Sept 21 (Reuters) - The U.S. Food and Drug Administration on Tuesday approved Incyte Corp's cream for treating inflammatory skin condition atopic dermatitis, commonly called eczema, in adolescents and adults. (Reporting by Bhanvi Satija and Manojna Maddipatla; Editing by Vinay Dwivedi)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
53.07 USD | +0.25% | +4.03% | -15.21% |
05-01 | TD Cowen Adjusts Price Target on Incyte to $80 From $88 | MT |
05-01 | RBC Capital Adjusts Price Target on Incyte to $60 From $65 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.21% | 11.89B | |
-3.93% | 86.16B | |
+2.76% | 40.17B | |
-17.00% | 31.47B | |
+54.44% | 25.24B | |
-12.01% | 15.82B | |
-9.12% | 11.96B | |
-42.56% | 11.61B | |
+4.87% | 8.84B | |
-2.11% | 7.93B |
- Stock Market
- Equities
- INCY Stock
- News Incyte Corporation
- Incyte : FDA approves Incyte's eczema cream